We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+8.83%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$284M
Cap. Flow
+$340M
Cap. Flow %
29%
Top 10 Hldgs %
38.67%
Holding
102
New
36
Increased
28
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$31.2M
2
CAH icon
Cardinal Health
CAH
+$29.2M
3
VERA icon
Vera Therapeutics
VERA
+$28.8M
4
CVS icon
CVS Health
CVS
+$28.1M
5
LLY icon
Eli Lilly
LLY
+$23.2M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$35M
2
NVS icon
Novartis
NVS
+$23M
3
THC icon
Tenet Healthcare
THC
+$19.3M
4
ACLX
Arcellx
ACLX
+$15.1M
5
MDT icon
Medtronic
MDT
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 96.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTSG icon
26
BrightSpring Health Services
BTSG
$11.5B
$16.2M 1.38%
950,000
+450,000
+90% +$7.78M
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.94B
$15.3M 1.31%
300,000
– –
AZN icon
28
AstraZeneca
AZN
$247B
$14.7M 1.26%
+112,500
New +$15.8M
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.84B
$14.7M 1.25%
+550,000
New +$17.5M
JSPR icon
30
Jasper Therapeutics
JSPR
$32.2M
$13.9M 1.18%
650,000
+300,000
+86% +$6.25M
FMS icon
31
Fresenius Medical Care
FMS
$12.7B
$13.6M 1.16%
600,000
+150,000
+33% +$3.26M
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
$13.4M 1.14%
+420,000
New +$12.6M
MDT icon
33
Medtronic
MDT
$115B
$12M 1.02%
150,000
-150,000
-50% -$13M
ACHC icon
34
Acadia Healthcare
ACHC
$2.91B
$11.9M 1.01%
+300,000
New +$13.5M
DXCM icon
35
DexCom
DXCM
$33.4B
$11.7M 0.99%
150,000
+30,000
+25% +$2.22M
BNTX icon
36
BioNTech
BNTX
$23.2B
$11.4M 0.97%
100,000
+50,000
+100% +$5.71M
WAT icon
37
Waters Corp
WAT
$40.6B
$11.1M 0.95%
+30,000
New +$11M
TEVA icon
38
Teva Pharmaceuticals
TEVA
$42.5B
$11M 0.94%
+500,000
New +$9.1M
MLTX icon
39
MoonLake Immunotherapeutics
MLTX
$1.38B
$10.8M 0.92%
200,000
-20,000
-9% -$1.02M
MLYS icon
40
Mineralys Therapeutics
MLYS
$2.4B
$10.8M 0.92%
875,000
+519,000
+146% +$6.79M
JANX icon
41
Janux Therapeutics
JANX
$1.02B
$10.7M 0.91%
+200,000
New +$10.6M
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$29.3B
$10.6M 0.9%
45,000
+20,000
+80% +$5.26M
HUM icon
43
Humana
HUM
$45.2B
$10.1M 0.87%
+40,000
New +$10.7M
OSCR icon
44
Oscar Health
OSCR
$8.68B
$9.41M 0.8%
+700,000
New +$11.3M
COO icon
45
Cooper Companies
COO
$15B
$9.19M 0.78%
100,000
-10,000
-9% -$1.02M
KRYS icon
46
Krystal Biotech
KRYS
$9.7B
$8.62M 0.73%
+55,000
New +$9.76M
EXAS
47
DELISTED
Exact Sciences
EXAS
$8.43M 0.72%
150,000
+70,000
+88% +$4.36M
RYTM icon
48
Rhythm Pharmaceuticals
RYTM
$7.91B
$8.4M 0.72%
+150,000
New +$8.29M
EWTX icon
49
CALL
Edgewise Therapeutics
EWTX
$4.84B
$8.01M 0.68%
300,000
-200,000
-40% -$6.37M
ETNB
50
DELISTED
89bio
ETNB
$7.82M 0.67%
1,000,000
+500,000
+100% +$4.12M
1
2
3 4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Integral Health Asset Management held 102 positions worth $1.17B, up 32% from $889M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Integral Health Asset Management deployed $340M of net new capital in Q4 2024, opening 36 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 500,000 shares worth $30.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $19.3M trimmed.

  • Integral Health Asset Management's largest Q4 2024 buy was Centene: 500,000 shares worth $30.3M.
  • Integral Health Asset Management added most to Vera Therapeutics in Q4 2024, an estimated $28.8M increase.
  • Integral Health Asset Management's biggest Q4 2024 reduction was Tenet Healthcare, cutting an estimated $19.3M.
  • Integral Health Asset Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $35M.
  • Integral Health Asset Management's ten largest holdings make up 39% of its $1.17B portfolio in Q4 2024.
  • Integral Health Asset Management opened 36 new positions and closed 19 in Q4 2024.
  • Integral Health Asset Management's portfolio value rose 32% quarter-over-quarter to $1.17B.

Based on Integral Health Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.